ANALYSIS OF XEPLION LONG-TERM TREATMENT OF SCHIZOPHRENIA PATIENTS
Effectiveness and safety analysis of Xeplion long-term treatment of patients with recently diagnosed schizophrenia was conducted. 28 patients were given Xeplion as regular treatment. During the 12-month research dynamics of clinical symptoms were assessed by PANSS and quality of life was assessed by PSP scale. The research results showed that during Xeplion treatment remission was of better quality, that was reflected in significant reduction of PANSS scores in positive, negative and general scales, and in quality of life improvement, assessed by PSP scale. There was the only one hospitalization during the observation period, side effects were seldom. Good tolerance and effectiveness profiles allow to recommend Xeplion for prescribing to patients with first psychotic episode.